A tau PET study for non-AD tauopathies

Takano Harumasa0 sites80 target enrollmentDecember 22, 2023

ConditionsProgressive Supranuclear PalsyCorticobasal SyndromeMild Cognitive Impairment D013494, D000088282, D060825

Overview

Phase: 未知
Intervention: Not specified
Conditions: Progressive Supranuclear PalsyCorticobasal SyndromeMild Cognitive Impairment
Sponsor: Takano Harumasa
Enrollment: 80
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 22, 2023

End Date

TBD

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Takano Harumasa

Eligibility Criteria

Inclusion Criteria

•Patient group
•(common part)
•1\) Persons who are 50 years of age or older at the time of obtaining consent regardless of gender
•2\) Currently attending our hospital or having participated in research, and falls under any of A, B, or C below.
•3\) There is a study partner who communicates with participants at least once a week and who serves as an information provider.
•(Contact with research subjects may be face\-to\-face, by telephone, email, etc.).
•4\) Those who have blood or cerebrospinal fluid specimens in the NCNP biobank, or those who plan to collect specimens.
•A. Progressive Supranclear Palsy (PSP)
•a) Those who are clinically diagnosed with PSP according to the diagnostic criteria of the Basic Research Group in the Field of Neurodegenerative Diseases
•B. Corticobasal Syndrome (CBS)

Exclusion Criteria

•1\. Patients
•1\) Proven to have multiple cerebral infarctions, normal pressure hydrocephalus, brain tumors, epilepsy, subdural hematoma, multiple sclerosis, or head trauma with residual symptoms or brain structural abnormalities
•2\) Exhibiting local lesions on MRI, such as infections and cerebral infarctions, which could affect cognitive function. Asymptomatic deep small infarctions and mild white matter changes are deemed acceptable for inclusion, but atheromal thrombosis and cardiac embolism, infarction with lesions in the cerebral cortex, or severe diffuse white matter changes (Fazekas grades equal to or above 3\) are excluded.
•3\) Possessing an implanted pacemaker, aneurysm clip, artificial inner ear, or other magnetic/electric conductive metals or being unable to undergo MRI because of claustrophobia
•4\) Having allergy to thioflavin derivatives
•5\) Having a history of major depressive disorder or bipolar disorder defined by Diagnostic Statistical Manual (DSM)\-V within 1 year prior or schizophrenia as defined by DSM\-5
•6\) Being comorbid with or having a history of alcohol/drug dependence as defined by DSM\-V within past 2 years
•7\) Exhibiting psychiatric symptoms, excitement, or behavioral disturbance to a degree that would have hindered their ability to follow the research protocol within the preceding three months
•8\) Having serious systemic diseases or unstable diseases
•9\) Currently participating in a clinical interventional study/trial or a history of having participated in anti\-amyloid trials